V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10433098 | 10065094 | 1.7 | 71.6 | null | 2014-04-19 | 2018-07-15 | Sunitinib | 02 | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 101550255 |
| 10433120 | 10065095 | null | 54.7 | Palliative (P) | 2016-12-23 | 2017-01-07 | Cisplatin + Fluorouracil + RT 5day | 02 | N | RUCAPARIB | 101538191 |
| 10433242 | 10065098 | 0 | 0 | null | 2019-05-18 | 2019-07-11 | Gemcitabine + Capecitabine | 02 | null | TRIAL | 101633082 |
| 10433349 | 10065100 | 1.83 | 88.3 | Palliative (P) | 2019-03-17 | 2019-03-23 | null | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100573943 |
| 10433380 | 10065101 | null | null | Curative (C) | 2020-01-20 | 2020-01-21 | Eribulin | null | N | BRENTUXIMAB | 101727333 |
| 10434009 | 10065102 | null | null | Palliative (P) | 2018-01-27 | 2018-01-27 | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 02 | null | AVAPRITINIB | 101751455 |
| 10434144 | 10065103 | 1.57 | 80.5 | Palliative (P) | 2019-09-08 | 2019-09-12 | IPILIMUMAB + PEMBROLIZUMAB | N | N | PEG INTERFERON | 100083176 |
| 10434471 | 10065105 | 1.7 | 73.2 | Palliative (P) | 2020-08-15 | 2020-08-22 | CARBO + FLUOROURACIL | 02 | N | DOCETAXEL + NINTEDANIB | 101375258 |
| 10435010 | 10065108 | 1.65 | 60 | null | null | 2021-11-19 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | null | TRABECTEDIN | 100332515 |
| 10435119 | 10065110 | 1.64 | 70 | 03 | 2020-07-16 | 2020-07-30 | Capecitabine + Mitomycin | 02 | N | CISPLATIN + PEMETREXED | 101095777 |
| 10435680 | 10065112 | 1.68 | null | 03 | 2019-09-23 | 2019-10-10 | Midostaurin | 2 | N | GEMCITABINE + NAB-PACLITAXEL | 100433817 |
| 10435795 | 10065114 | 1.74 | 68.5 | null | 2017-03-10 | 2017-03-23 | Pemetrexed | 02 | null | CYCLOPHOSPHAMIDE + RITUXIMAB | 100345746 |
| 10435928 | 10065115 | 1.55 | 0 | null | 2019-11-14 | 2019-11-14 | AXITINIB | 02 | null | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 101609344 |
| 10436800 | 10065119 | 0 | 78 | Palliative (P) | 2017-12-08 | 2018-03-01 | CARFILZOMIB | 02 | N | CARBOPLATIN + FLUOROURACIL | 101460756 |
| 10436872 | 10065121 | 1.71 | 61 | Curative (C) | 2021-07-09 | 2022-04-21 | null | 02 | N | TRIAL | 100898193 |
| 10437192 | 10065124 | 0 | 52.2 | null | 2017-12-12 | 2017-12-24 | R GCVP | 02 | null | CLADRIBINE + RITUXIMAB | 100214368 |
| 10437326 | 10065125 | 1.78 | 104.5 | null | 2020-01-19 | 2020-08-26 | Chlorambucil + Pred + Rituximab | 02 | N | DACARBAZINE | 100374440 |
| 10437947 | 10065126 | 1.8 | 68.2 | null | 2021-06-12 | 2021-10-15 | null | 02 | null | TOPOTECAN | 100152227 |
| 10438141 | 10065127 | 1.67 | 56.3 | null | null | 2021-06-14 | Eribulin | 99 | null | GEMCITABINE + NAB-PACLITAXEL | 101511436 |
| 10438175 | 10065128 | 1.75 | 80 | Palliative (P) | 2020-01-11 | 2020-01-18 | MYELOMA XI TRIAL | 02 | N | CARBOPLATIN + FLUOROURACIL | 100088426 |
| 10438319 | 10065129 | 1.72 | 115 | Palliative (P) | 2020-03-29 | 2020-03-29 | Ipilimumab | 02 | N | LENALIDOMIDE + RITUXIMAB | 100823772 |
| 10438624 | 10065131 | 0 | 67.5 | Adjuvant (A) | null | 2020-01-08 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | N | OCTREOTIDE | 100580316 |
| 10438757 | 10065133 | 1.81 | 79.7 | Palliative (P) | 2019-06-06 | 2019-06-12 | Bexarotene | 01 | N | RUCAPARIB | 101119060 |
| 10439142 | 10065136 | 1.55 | 89.4 | null | 2021-01-04 | 2021-03-05 | null | 02 | null | BENDAMUSTINE + THALIDOMIDE | 100337421 |
| 10439306 | 10065137 | null | null | Curative (C) | 2018-08-26 | 2018-09-03 | Ifosfamide | 02 | N | DASATINIB | 101529428 |
| 10439350 | 10065138 | 0 | 0 | Palliative (P) | 2019-11-20 | 2020-02-28 | null | 02 | N | VISMODEGIB | 101300168 |
| 10439777 | 10065140 | null | null | Palliative (P) | 2020-11-06 | 2021-01-28 | LOPP | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101179068 |
| 10440345 | 10065143 | null | null | Palliative (P) | null | 2019-01-28 | Liposomal Doxorubicin 50mg/m2 | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101581018 |
| 10440452 | 10065144 | 1.7 | 89.8 | null | 2020-01-09 | 2020-01-10 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 2 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE | 100945468 |
| 10440586 | 10065145 | 1.76 | 76.7 | null | null | 2020-07-31 | Eribulin | 02 | null | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 100119563 |
| 10440602 | 10065146 | 1.59 | 79.5 | Palliative (P) | 2021-12-30 | 2022-01-02 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 02 | N | PLATFORM TRIAL | 101184031 |
| 10440649 | 10065147 | 1.67 | 51.7 | null | 2020-04-05 | 2020-04-07 | GEMCITABINE + NAB PACLITAXEL | 02 | null | BCG | 100497212 |
| 10440928 | 10065148 | 1.76 | 90.9 | Palliative (P) | null | 2020-05-25 | ISATUXIMAB + POMALIDOMIDE | 02 | N | EVEROLIMUS | 101293525 |
| 10440931 | 10065149 | 1.65 | 64.65 | Palliative (P) | 2022-05-03 | 2022-05-03 | OSIMERTINIB | 02 | N | OSIMERTINIB | 101588954 |
| 10441740 | 10065153 | 1.8 | 69 | Disease modification (D) | 2020-12-20 | 2021-01-31 | AML17 TRIAL | 02 | N | BINIMETINIB + ENCORAFENIB | 100490571 |
| 10442009 | 10065154 | 1.66 | 75.6 | Palliative (P) | 2021-03-11 | 2021-04-14 | Bevacizumab | 02 | N | DASATINIB | 100067737 |
| 10442117 | 10065156 | 1.83 | 86 | Palliative (P) | 2021-07-18 | 2021-08-03 | null | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 101357773 |
| 10442274 | 10065157 | 1.8 | 80 | Palliative (P) | 2017-12-30 | 2018-01-17 | EVEROLIMUS | 2 | N | CHOP R | 100643558 |
| 10442870 | 10065159 | 1.66 | 64 | null | 2017-05-05 | 2017-06-11 | null | null | null | IRINOTECAN + MDG | 100932057 |
| 10443050 | 10065160 | 1.66 | 72.2 | null | null | 2018-11-17 | Durvalumab | 02 | null | BEXAROTENE | 100517493 |
| 10443097 | 10065161 | 1.67 | 81.8 | null | null | 2018-03-27 | BLEOMYCIN | 02 | N | BEVACIZUMAB + OLAPARIB | 100035968 |
| 10443134 | 10065162 | 0 | 72.4 | 03 | 2017-02-22 | 2017-02-22 | PEG INTERFERON | 2 | N | NAB-PACLITAXEL | 101088808 |
| 10443238 | 10065163 | 1.73 | 80.7 | null | null | 2016-10-05 | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + VINCRISTINE | 02 | null | SAPROCAN TRIAL | 100560162 |
| 10443345 | 10065164 | 1.68 | 87.4 | null | 2016-11-11 | 2018-10-30 | VISMODEGIB | 01 | null | FLUOROURACIL + MITOMYCIN | 101810969 |
| 10443511 | 10065165 | 1.83 | 62.5 | Palliative (P) | null | 2019-04-23 | Capecitabine + Cisplatin | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100727658 |
| 10443658 | 10065166 | 1.72 | 87.12 | Adjuvant (A) | 2016-10-21 | 2017-03-29 | OSIMERTINIB | 02 | N | EOX | 100368663 |
| 10443699 | 10065167 | 1.63 | 62 | null | null | 2019-04-09 | Durvalumab | 02 | null | CISPLATIN + PEMETREXED | 100521879 |
| 10443771 | 10065168 | 1.71 | 65 | null | 2021-11-30 | 2021-12-08 | Obinutuzumab +CVP | 02 | null | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 101318243 |
| 10443885 | 10065170 | 1.59 | 46.5 | Curative (C) | 2017-09-11 | 2017-09-28 | Fulvestrant + Ribociclib | null | N | ETOPOSIDE | 101100238 |
| 10444106 | 10065173 | 1.77 | 84.15 | Curative (C) | 2016-11-19 | 2016-11-19 | null | 02 | N | CHLORAMBUCIL + RITUXIMAB | 101678517 |